{"name":"Recipharm","slug":"recipharm","ticker":"PRIVATE","exchange":"Private (EQT-owned)","domain":"recipharm.com","description":"Recipharm is a leading global Contract Development and Manufacturing Organisation (CDMO), employing 5,200 people and operating in over a hundred markets worldwide.","hq":"Stockholm, Sweden","founded":0,"employees":"","ceo":"Marc Funk","sector":"CDMO / Contract Manufacturing","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"~$3.5B (EQT valuation)","metrics":{"revenue":1600000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lynparza patent cliff ($1.4B at risk)","drug":"Lynparza","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Keytruda patent cliff ($14.5B at risk)","drug":"Keytruda","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-15","type":"deal","headline":"Recipharm Acquires Catalent's Clinical Supply Business","summary":"Recipharm has acquired Catalent's clinical supply business, expanding its capabilities in clinical supply services.","drugName":"","sentiment":"positive"},{"date":"2022-08-24","type":"earnings","headline":"Recipharm Reports Strong H1 2022 Results","summary":"Recipharm reported strong half-year results, with revenue growth and increased profitability.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOcXIzbzVqNGhzc19lZnhWV1EtbXJEVUUzd1BrWjJsUGFUNFdUVEZDR2wzbTlya3ZGbmh2b19kWVhvRDhOQldrLXJIOXp0Z3ZfV2VmNGdfT0Vja2JtNk83Nk9rajVBLTExclJXRGhVUGZoNDl6U3NDSzFjbzZiUEJPeXQ3UEQ0SlpBX0F5cmdJbFl3X096dGtucDM1Zlk?oc=5","date":"2026-03-06","type":"deal","source":"pehub.com","summary":"PE eyes growth opportunities in active pharmaceutical ingredients: 5 deals - pehub.com","headline":"PE eyes growth opportunities in active pharmaceutical ingredients: 5 deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVVZXVUhsakUxV2ZUY2lNNVBuZlNwRUdFVEtOdmxGbWZmem44aFFTV1hBTHl5dUZmWWNOaTlQQ3BvOE1GbVV0cDVNWS1kcWlCTkYwYVVKaE91cWd6MXdfVmtjZU90ZVp5a2FyeG01OXA1bC1DSHJzZU5NLXV5b3cwYVJudjBWRnJaMDlyT08xLVFZNi16eVRfVENYNG1wYUcwSWtZY2czY3l3ZW9PSW14Z0lhNA?oc=5","date":"2026-02-18","type":"deal","source":"Fierce Pharma","summary":"Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership - Fierce Pharma","headline":"Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOTDl1ZkRld3Rxd3F4bUo1a1hCRG5PU1g5UnZ2clpsUzNGV1Fmd1dKMEJVNFp1T0pRR3BscUV6cFk2cWdLWkljTElPZzlYeTRxN0h0bnlLMm1WcFBrbDM5UDV5ZU1UeFRVanVSYVljb0FDc3dTekRTSDl5bHFfTkEtV2tacFkySEtzZVhnWnd0TGJKN0xOb2Nfbm1LYWlCUQ?oc=5","date":"2025-07-30","type":"pipeline","source":"Yahoo Finance","summary":"Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific - Yah","headline":"Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1ZRF85ZkM2eGhlX2w5T0tscVNQUTY1TGhnQ2Jmd2lnVVl2TE41NXdxcDhpYk41Yk13Z3g4bnNiOFBFMVQwamRWQXdIMnZFVDZQaVB0SzBKSXpTTHB3VnJpTmJHd05ZVmpSSmhpblVNbHh3QUMzU2o4?oc=5","date":"2025-05-14","type":"regulatory","source":"Pharmaceutical Technology","summary":"Recipharm, PLG to back pharma firms to expedite market approval - Pharmaceutical Technology","headline":"Recipharm, PLG to back pharma firms to expedite market approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNUlZMMHptYUtad2pXcnhQcHFYeWVkdGRRRk5aM2FxeEFQWmlRT2wwOEY2aFoyektiMzlueUNkdVZqSHBlWDB4YXRkd2VDMWVTN245NFFJZkdPdFhLZ2JkZXltRVQwcHdUcnQyYjF3SkpGcFNuYXM4RmRveFhzWW9XUWI3MFRCRUp1dGk5SHI0c0RiNG5wRS1xcjBPNW5JU1U5dURycDFuZlJQVEE?oc=5","date":"2025-04-21","type":"pipeline","source":"Fierce Pharma","summary":"Meribel makes CDMO debut after series of acquisitions in Europe - Fierce Pharma","headline":"Meribel makes CDMO debut after series of acquisitions in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOWEE3bV9CNXBmOW9wYVcyenJZdjlSSk9LdWhpakVKZ0RlTjdVaXVna3RCZHNhWU5kLWZRVU5vQ2tUQmxnZkI0NzZoU3kzQjRaWnFURGhvY1lGS0xnTVc3VHBKRGRSSjloVGMwMExjaXRPYWF6X1cwMkgzVW5FMnZEeUdaTk1ZYlZSTHdXOHppUEwwVzg?oc=5","date":"2025-04-16","type":"pipeline","source":"PharmTech.com","summary":"New CDMO Meribel Pharma Solutions Launches with 13 Sites in Europe - PharmTech.com","headline":"New CDMO Meribel Pharma Solutions Launches with 13 Sites in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1pczNQTXZPVHJ5TEU4cERWcnhnRTdzaWhSc0pjZzRiN0RCUnNGQVhUWWhieDd2ampjeW9Xb00zNC1vZmZoOFBSWTlhcUs1UVg3ajdaWlUxMVFmb3BsUEhXRHlBcWlybUppSDlVbTc5T2RtNkZkS3lIeEphWmrSAYIBQVVfeXFMUHZWQmJKZk9qM2Z6dHNpQXMtZ1V0bGoxT091dFNEYTZCMWotRG5Ic181NUNURmtQVjBFR0x4Wk54aXlRMWxqVEF1VGZHY01WVjJSQ1U3YjJ3a3hmRVNrYzNMSmlzQkFSSm1KaG5sRi1PY3NLTEtwYnRSVW1SSWJlVFc3QQ?oc=5","date":"2024-09-29","type":"deal","source":"Pulse 2.0","summary":"Blue Wolf Capital Partners Creates New CDMO Platform - Pulse 2.0","headline":"Blue Wolf Capital Partners Creates New CDMO Platform - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE0xbnRWNVhIRzROWHJkWk9VeGtDbmFXdWU4b1VILVpqZWhRNHZmcEwxLTlLazdiOG93ZmE0TmhyMFZjQ2dzNi1Pa0JfQlNvOUl3dkhMYkVQNnRWUjBKTE5GWWNkS0VDU3FWZjRnR2otQmtKX1k0M1l2enpCcWY0WUE?oc=5","date":"2024-07-02","type":"pipeline","source":"pe-insights.com","summary":"EQT makes $2.8 billion bid for drugmaker Recipharm - pe-insights.com","headline":"EQT makes $2.8 billion bid for drugmaker Recipharm - pe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUElrdEpoR2paZnpKNHNJR2RFU3l5c0xjaERQX3RTenhfamxDa2liTVdzaURub3lXYzlyYjdLcm9GTHNfUkdQbEZESVJLWUZtbmZaeksxSklaVUM1OWpNaFBkT2RkYVBQbWIxWmJJQWotM3JNa0VXOVZEeWFQSHd6VVJlcE5LSVM4SXhvOU9QRlU3NjlvSHYwM0xvcnFvSktUWFpkdXkyd1lpeGJobEY1Rl83YmZmOWYyYjM4?oc=5","date":"2024-04-02","type":"pipeline","source":"BioPharma APAC","summary":"Bespak Completes Separation from Recipharm,Shifts Focus to Low GWP Inhalers - BioPharma APAC","headline":"Bespak Completes Separation from Recipharm,Shifts Focus to Low GWP Inhalers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQaUpLWHl2SjZvaklfWk9iSXJjR204Mi1kWmtIWF9WMUl6WktGT3BiaGx3SjEzbWFyZGhTblhyX3FxY2JWV1YyekZrRU5tQnlEMzZsVmd6S3l0WjBuT3kxcTFKdHlmMG55eEo0R0Q0Q19pRzBYQ0hGVlhzSktGc0JiNXYxZDFMWWRFNTJBMkNyUW5meGJfTHNvRWkteE5rekFYd1NWclpqdXk4OER0?oc=5","date":"2020-12-14","type":"deal","source":"Bloomberg.com","summary":"EQT Offers to Buy Recipharm of Sweden in $2.1 Billion Deal - Bloomberg.com","headline":"EQT Offers to Buy Recipharm of Sweden in $2.1 Billion Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNVnBSMHVNTzJrd0JwNkFqcEZHUHNhaDhRdWtQLWttUFk1UzdpN0R0NHMxcDhENkRjcVJxYlY1OC1Hcm84TndlTmxlaDFPWTNHb0xzb3djY1lpZ2twMXZGbUtxSGstdUdlcnFjc3NkVUJMYkhJT0xWNS1WaE9YODVOX3lZSjhKU1FJOUNJYWZ4TGNid2Z1SVpaetIBngFBVV95cUxQN0VMMEt5ZDFDXzk1NlNRdHA1eHdxVDVBMFE2Q1JXdkFrMFBKVXBQb3hhMlljS3pPSWVsSG1FN1VBNTNnWGpLQzB6NlJNMkMxZ2lQYnJ4SlE4djRLcUZaWWJCOG1ubnFkNUlMSWo1RExNd0YydUJBb2dLcFVtNldwRVVaZkpRaHd6ejUwZkJaVjJPTHNQS1haaHpYbkhMQQ?oc=5","date":"2020-12-14","type":"pipeline","source":"Private Equity News","summary":"EQT makes bid for Recipharm valuing company at $2.8bn - Private Equity News","headline":"EQT makes bid for Recipharm valuing company at $2.8bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNd0VlMm52MHY3aUQ1U1hMOHd6SXBEWTNPcjFjMkJaZG4zdnNPZTU5U2NGWEpBQWtnVFZ1S1EyaEk4X0dHOVo0R1NmMkExYW50UmhCVEg4YVRQVkxzdlpWVFZUdFlhMkJpSGpXbF9sNXB2S3dySENPbFRTeC1EUHc5bkd3Qm1NMUZxdFhfOEl2VTBiMnJmVWp0aTZKUW83UnNhdlhjWlBBblEyNDNN?oc=5","date":"2016-12-30","type":"regulatory","source":"Contract Pharma","summary":"Recipharm Gains Approval for Acquisition of Kemwell Indian Ops - Contract Pharma","headline":"Recipharm Gains Approval for Acquisition of Kemwell Indian Ops","sentiment":"positive"}],"patents":[{"drugName":"Lynparza","drugSlug":"olaparib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Keytruda","drugSlug":"pembrolizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":14500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Catalent","Lonza","Piramal"],"therapeuticFocus":["Oncology","Autoimmune Diseases"],"financials":null,"yahoo":null}